MedTrace Logo

Alvocade® (Bortezomib) Safety and Effectiveness Study

NCT06012383 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 57

Last updated 2023-08-25

No results posted yet for this study

Summary

This study is a phase IV, post-marketing, observational, cohort study for safety and effectiveness evaluation of Alvocade® use in Iranian patients with multiple myeloma. No control groups were considered in the study design. The primary objective of this study was safety assessment, including the incidence of adverse events (AEs).

Conditions

  • Multiple Myeloma, Refractory

Interventions

DRUG

Bortezomib

Alvocade® was given with a dose of 1.3 mg/m2.

Sponsors & Collaborators

  • NanoAlvand

    lead INDUSTRY

Principal Investigators

  • Mani Ramzi, Prof. · Shiraz University of Medical Sciences, Shiraz, Iran

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2022-12-31
Completion
2022-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06012383 on ClinicalTrials.gov